Waldenström macroglobulinemia and relationship to immune deficiency.
Waldenstrom macroglobulinemia
immune deficiency
immunosuppression
real-life experience
relationship
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
pubmed:
5
6
2021
medline:
3
11
2021
entrez:
4
6
2021
Statut:
ppublish
Résumé
Primary or secondary immune deficiency (ID) is a risk factor, although rare, to develop Waldenström macroglobulinemia (WM). We aimed to better understand the incidence of this occurrence in the real-life and the outcome of either entity. We conducted a review of 194 WM in the Poitou-Charentes registry and identified 7 (3.6%) with a prior history of ID. Across the 7 WM with ID, 4 progressed to active WM disease and required treatment for WM with a median time between WM diagnosis and the first treatment of 1.5 years (range 0-3). The median time from ID to WM occurrence was 8 years (1-18). WM could develop from ID, although a rare event. Our first action was to systematically decrease immunosuppression with long-term control of ID. Half of indolent WM remained indolent despite ID and for remaining WM none appeared of poor risk WM.
Identifiants
pubmed: 34085595
doi: 10.1080/10428194.2021.1907379
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM